NCT06916403View on ClinicalTrials.gov

Safety and Efficacy of Ketamine Intravenous Infusions in the Treatment of Fibromyalgia

Active, not recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
Fibromyalgia
Interventions
DRUG

Intravenous Ketamine Infusions

Ketamine will be slowly infused with the routine target dose 1.5-2 mg/kg over 3-4 hours.

Trial Locations (1)

L4J 1W3

Wilderman Medical Clinic, Thornhill

All Listed Sponsors
lead

Wilderman Medical Clinic

OTHER